Synthesis of Self-Complementary CaVitands
J. Am. Chem. Soc., Vol. 122, No. 19, 2000 4581
in anhydrous solvents under a nitrogen atmosphere. Compounds 1,27
1,2-difluoro-4,5-dinitrobenzene,28 1,2-diketopyracene,29 and 2,3-di-
hydroxy-6-quinoxalinecarboxylic acid30 were synthesized in accord
with the literature protocols. Molecular modeling was performed using
the Amber* force field in the MacroModel 5.5 program.31
Benzyl Ester 14. A suspension of 2,3-dihydroxy-6-quinoxaline-
carboxylic acid (0.207 g, 1.0 mmol) in SOCl2 (4 mL) was treated with
a catalytic amount of DMF and heated at 80 °C for 3 h. After being
cooled to room temperature the clear yellow solution was concentrated
to give 2,3-dichloro-6-quinoxalinecarbonyl chloride as a tan solid. This
material was then dissolved in 5 mL of CH2Cl2 and cooled at 0 °C.
The solution was treated with triethylamine (0.404 g, 0.57 mL, 4.0
mmol) and then benzyl alcohol (0.108 g, 0.103 mL, 1.0 mmol) and
allowed to warm to room temperature. After being stirred for 16 h, the
reaction mixture was poured into a mixture of 10% K2CO3 and CH2-
Cl2. The layers were separated and the organic phase washed with brine,
dried over MgSO4, filtered, and concentrated to give ca. 0.30 g of the
crude product. Column chromatography (0-20% EtOAc-hexane)
provided 0.261 g of 14 as a tan solid: mp 111-112 °C; FTIR (CHCl3,
Hexanitrocavitand 8. Triethylamine (2.23 mL, 16.0 mmol) was
added dropwise to a stirred solution of resorcinarene 1 (1.10 g, 1.0
mmol) and 1,2-difluoro-4,5-dinitrobenzene (0.612 g, 3.0 mmol) in
anhydrous DMF (50 mL). The resulting mixture was then heated to 70
°C and kept at that temperature for 16 h. The reaction mixture was
cooled to room temperature and poured into dilute aqueous HCl (pH
∼1, 400 mL). The bright yellow solids were filtered off, washed with
large amount of water, and dried in vacuo. Column chromatography
(CH2Cl2, then 2% MeOH-CH2Cl2) provided first the octanitro
compound (0.370 g; 0.21 mmol; 21%) and then the desired hexanitro
cavitand 8 (0.910 g; 0.57 mmol; 57%) as a yellow solid after trituration
with MeOH: mp >250 °C; FTIR (CHCl3, cm-1) υ 3578, 2919, 2851,
1590, 1543, 1490, 1343, 1286, 1195; 1H NMR (600 MHz, CDCl3,
330K) δ 7.63 (s, 2 H), 7.61 (s, 2 H), 7.58 (s, 2 H), 6.95 (s, 2 H), 6.84
(s, 2 H), 6.70 (s, 2 H), 6.60 (s, 2 H), 5.85 (s, 2 H), 4.31 (t, J ) 7 Hz,
1 H), 4.00-3.97 (m, 3 H), 2.10-2.01 (m, 8 H), 1.36-1.28 (m, 72 H),
0.90 (t, J ) 7 Hz, 12 H); MS-ESI- m/z 1597 ([M - H + 13C]- calcd
for C89H111N6O2013C 1597).
1
cm-1) υ 2995, 1719, 1452, 1381, 1295, 1267, 1152, 1119, 1000; H
NMR (600 MHz, CDCl3) δ 8.78 (d, J ) 1.4 Hz, 1 H), 8.44 (dd, J )
1.4, 9 Hz, 1 H), 8.10 (d, 9 Hz, 1 H), 7.51-7.35 (m, 5 H), 5.46 (s, 2
H); 13C NMR (150 MHz, CDCl3) δ 164.8, 147.5, 146.6, 142.5, 139.9,
135.3, 132.5, 130.97, 130.7, 128.7, 128.6, 128.5, 128.4, 67.6; HRMS-
MALDI-FTMS m/z 333.0194 ([M + H]+, calcd for C16H11Cl2N2O2
333.0198, error 1.2 ppm). Analogously, 2,3-dichloroquinoxalines 13a,b
and 15 were synthesized from 2,3-dichloro-6-quinoxalinecarbonyl
chloride and 1-aminoadamantane, 1-aminomethyladamantane, and
1-adamantanol.
Hexaamide 9. A solution of hexanitro cavitand 8 (3.92 g, 2.45 mmol)
in toluene (150 mL) was treated with a catalytic amount of Raney
Nickel as a suspension in EtOH (commercial H2O suspension was pre-
washed with EtOH (2 × 5 mL)). The mixture was stirred for 16 h at
40 °C under a H2 atmosphere. After cooling, the mixture was filtered
through a pad of Celite with the aid of MeOH (2 × 50 mL). The filtrates
were combined and evaporated under vacuum to give a brown solid
(3.52 g) that was protected from air and used directly in the next step.
The crude hexaamine was dissolved in 150 mL of degassed (purged
with N2) EtOAc-water (1:1) and K2CO3 (4.01 g, 29.4 mmol) was added
with vigorous stirring. Octanoyl chloride (2.39 g, 2.50 mL, 14.7 mmol)
was added at once, and the resulting mixture was stirred at room
temperature for 2 h. The solution was then diluted with half-saturated
NaHCO3 and extracted with EtOAc. The combined organic extracts
were washed with brine, dried over MgSO4, filtered, and concentrated
to give 5.40 g of the crude amide. The crude amide product was
dissolved in 60 mL of toluene-EtOH (1:1) and treated with hydrazine
hydrate (0.613 g, 0.59 mL, 12.3 mmol). The mixture was stirred at 80
°C for 3 h, cooled to room temperature, and concentrated. Column
chromatography (0-1% MeOH in CH2Cl2) provided the product 9 as
a yellow solid after trituration with MeOH (1.44 g, 27% overall): mp
>250 °C; FTIR (CHCl3, cm-1) υ 3684, 3234, 2919, 2852, 1704, 1657,
General Procedure for the Coupling of Hexaamide 9 with 2,3-
Dichloroquinoxalines: Synthesis of Cavitands 4a-d. An oven-dried
10 mL flask was charged with hexaamide 9 (0.019 g, 0.0087 mmol)
and the quinoxaline 13a (3.6 mg, 0.0096 mmol). The reactants were
dissolved in dry DMF (1 mL) and the solution treated with triethylamine
(7 µL, 0.052 mmol). The reaction mixture was heated at 65 °C for 20
h and then allowed to cool to room temperature. The solution was
poured into a mixture of EtOAc (10 mL) and dilute aqueous HCl (10
mL). The layers were separated and the aqueous phase extracted with
two 10 mL portions of ethyl acetate. The combined organic extracts
were washed with brine, dried over Na2SO4, filtered, and concentrated
to provide 0.024 g of the crude product. Column chromatography (0-
20% EtOAc-hexane) provided 9 mg (42%) of cavitand 4a as a pale
yellow oil: FTIR (CHCl3, cm-1) υ 3244, 3014, 2918, 2852, 1657, 1514,
1
1481, 1400, 1324, 1276, 895 cm-1; H NMR (Figure 3A, 600 MHz,
p-xylene-d10) δ 10.3 (s, 1 H), 9.87 (s, 1H), 9.85 (s, 1 H), 9.79 (s, 1 H),
9.68 (s, 1 H), 9.54 (s, 1 H), 8.9 (s, 2 H), 8.05-7.15 (12 s, 15 H),
6.35-6.25 (m, 4 H), 6.01 (s, 1H), 5.90 (br tr, 1 H), 3.1-1.1 (m, 152
H), 1.0-0.8 (m, 30 H), 0.8-0.7 (m, 6 H), -0.58 (s, 3 H), -0.83 (d,
J ) 11 Hz, 3 H), -1.07 (d, J ) 11 Hz, 3 H); MALDI-MS m/z 2536
([M + Na]+ calcd for C157H226ClN9O15Na 2536).
1
Cavitand 4b: 11 mg of pale yellow oil, 51%; FTIR (CHCl3, cm-1
υ 3244, 3014, 2928, 2852, 1657, 1510, 1481, 1405, 1271, 890 cm-1
)
;
1600, 1514, 1481, 1404, 1276; H NMR (600 MHz, benzene-d6, 340
K) δ 9.85 (s, 2 H), 9.55 (s, 2 H), 8.70-8.80 (br s, 2 H), 7.74 (s, 2 H),
7.72 (s, 2 H), 7.62 (s, 2 H), 7.60 (s, 2 H), 7.39 (s, 2 H), 7.36 (s, 2 H),
7.07 (s, 2 H), 6.29 (t, J ) 8 Hz, 2 H), 6.23 (t, J ) 8 Hz, 1 H), 4.73 (t,
J ) 8 Hz, 1 H), 2.5-1.20 (m, 152 H), 0.94-0.90 (m, 30 H); 13C NMR
(150 MHz, benzene-d6, 330 K) δ 173.6, 173.4, 173.2, 156.4, 156.1,
155.8, 153.0, 151.3, 151.1, 137.3, 136.9, 132.5, 130.4, 129.5, 124.7,
124.5, 122.4, 121.3, 117.4, 111.7, 38.6, 37.6, 35.5, 34.8, 34.4, 34.3,
34.0, 33.5, 32.7, 32.5, 32.47, 32.4, 30.8, 30.63, 30.6, 30.55, 30.5, 30.3,
30.2, 29.9, 29.86, 29.6, 29.1, 29.0, 27.0, 26.95, 26.3, 23.4, 23.3, 14.6,
14.5; HRMS-MALDI-FTMS m/z 2196.5792 ([M + Na]+, calcd for
1H NMR (Figure 3B, 600 MHz, p-xylene-d10) δ 10.75 (s, 1 H, minor
diastereomer), 10.1-9.4 (9 s, 5 H, both diastereomers), 9.1-8.8 (3 s,
2 H, both), 8.4-7.0 (14 s, 17 H, both), 6.4-6.3 (m, 4 H, both), 5.9 (s,
1H, major diastereomer), 5.7 (s, 1 H, minor), 2.9-1.1 (m, 154 H),
1.1-0.8 (m, 30 H), 0 to -0.6 (m, 15 H); MALDI MS m/z 2551
([M + Na]+ calcd for C158H228ClN9O15Na 2550).
Cavitand 4c: 13 mg of pale yellow oil, 65%; FTIR (CHCl3, cm-1
)
υ 3407, 3244, 2919, 2851, 1714, 1662, 1600, 1509, 1481, 1405, 1267,
1195; 1H NMR (600 MHz, CDCl3) δ 9.56 (s, 1 H), 9.47 (s, 1 H), 9.37
(s, 1 H), 9.15 (s, 1 H), 8.72 (s, 1 H), 8.24 (d, J ) 9 Hz, 1 H), 8.1 (s,
1 H), 7.73 (s, 1 H), 7.63 (d, J ) 9 Hz, 1 H), 7.51-7.06 (8 s, 12 H),
6.70 (s, 1 H), 6.50 (s, 1 H), 5.86 (t, J ) 8 Hz, 1 H), 5.83, (t, J ) 8 Hz,
1 H), 5.73 (t, J ) 8 Hz, 1 H), 4.25 (t, J ) 8 Hz, 1 H), 3.99 (dd, J )
5 Hz, 5 Hz, 2 H), 2.5-1.0 (m, 167 H), 1.0-0.8 (m, 30 H); MALDI
MS m/z 2552 ([M + Na]+ calcd for C158H227ClN8O16Na 2551).
C138H208N6O14Na 2196.5645, error 6.7 ppm).
(26) For details on high-resolution mass spectrometry, see: (a) Rose,
M. E.; Johnstone, R. A. W. Mass Spectrometry for Chemists and
Biochemists; Cambridge University Press: Cambridge, 1982. (b) Jennings,
K. R.; Dolnikowsi, G. G. Methods in Enzymology; McCloskey, J. A., Ed.;
Academic Press: New York, 1990; p 37 and references therein.
(27) Tunstad, L. M.; Tucker, J. A.; Dalcanale, E.; Weiser, J.; Bryant, J.
A.; Sherman, J. C.; Helgeson, R. C.; Knobler, C. B.; Cram, D. J. J. Org.
Chem. 1989, 54, 1305-1312.
(28) Kazimierczuk, Z.; Dudycz, L.; Stolarski, R.; Shugar, D. Nucleosides,
Nucleotides 1981, 8, 101-117.
(29) Richter, H. J.; Stocker, F. B. J. Org. Chem. 1959, 24, 366-368.
(30) Kleb, K. G.; Siegel, E.; Sasse, K. Angew. Chem., Int. Ed. 1964, 3,
408.
Cavitand 4d: 0.104 g of pale yellow oil, 55%; FTIR (CHCl3, cm-1
)
1
υ 3407, 3244, 2928, 2852, 1719, 1657, 1514, 1486, 1404, 1267; H
NMR (600 MHz, CDCl3) δ 9.62 (s, 1 H), 9.54 (s, 1 H), 9.32 (s, 1 H),
9.13 (s, 1 H), 8.76 (s, 1 H), 8.24 (d, J ) 9 Hz, 1 H), 7.79 (s, 1 H), 7.69
(s, 1 H), 7.60 (d, J ) 9 Hz, 1 H), 7.50-7.04 (8 s, 18 H), 6.85 (s, 1 H),
6.70 (s, 1 H), 5.85 (t, J ) 8 Hz, 1 H), 5.82, (t, J ) 8 Hz, 1 H), 5.71
(t, J ) 8 Hz, 1 H), 5.42 (dd, J ) 8 Hz, 2 Hz, 2 H), 4.27 (t, J ) 8 Hz,
1 H), 2.5-1.0 (m, 152 H), 1.0-0.8 (m, 30 H); MALDI MS m/z 2509
([M + K]+ calcd for C154H217ClN8O16K 2509).
(31) Mohamadi, F.; Richards, N. G.; Guida, W. C.; Liskamp, R.; Lipton,
M.; Caufield, C.; Chang, G.; Hendrickson, T.; Still, W. C. J. Comput. Chem.
1990, 11, 440-467.